Skip to main content

SKYRIZI®

Risankizumab (ABBV-066) is an anti-IL-23 antibody approved for the treatment of multiple inflammatory diseases, including psoriasis, psoriatic arthritis, and Crohn's disease. It is also being investigator for the treatment of ulcerative colitis.

Type of Molecule

Biologic

Target

IL-23

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Crohn's Disease US - Approved,EU - Submitted
Approved
Psoriatic Arthritis US,EU
Approved
Psoriasis US,EU
Approved
Ulcerative Colitis n/a
Phase 3